Tadalafil
- Generic Name
- Tadalafil
- Brand Names
- Adcirca, Alyq, Cialis, Entadfi, Tadliq, Talmanco (previously Tadalafil Generics), Tadalafil Mylan, Tadalafil Lilly, Adcirca (previously Tadalafil Lilly)
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19N3O4
- CAS Number
- 171596-29-5
- Unique Ingredient Identifier
- 742SXX0ICT
- Background
Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy. It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like sildenafil, tadalafil has greater selectivity fo...
- Indication
Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with finasteride for the treatment of benign prostatic hypertrophy (BPH). It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with macitentan or other endothelin-1 antagonists.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Erectile Dysfunction, Pulmonary Arterial Hypertension (PAH)
- Associated Therapies
- -
Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Carelon Research
- Target Recruit Count
- 23
- Registration Number
- NCT01910389
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Miller School of Medicine University of Miami, Miami, Florida, United States
Chemoimmunotherapy and Radiation in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 10
- Registration Number
- NCT01903083
- Locations
- 🇺🇸
Portland Providence Medical Center, Portland, Oregon, United States
A Study of Tadalafil for Duchenne Muscular Dystrophy
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 331
- Registration Number
- NCT01865084
- Locations
- 🇵🇷
University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico
🇺🇸University of California, Davis - Health Systems, Sacramento, California, United States
🇺🇸Children's Hospital, Aurora, Colorado, United States
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease
- Conditions
- Interventions
- First Posted Date
- 2013-05-24
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 44
- Registration Number
- NCT01862536
- Locations
- 🇺🇸
Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States
🇺🇸VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States
🇺🇸VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States
A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)
- Conditions
- Interventions
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT01824290
- Locations
- 🇧🇷
Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
🇵🇱Uniwersytecki Szpital Dzieciecy w Krakowie-Prokocimiu, Krakow, Poland
🇩🇪Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany
REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs
- Conditions
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 120
- Registration Number
- NCT01803828
- Locations
- 🇮🇹
Dipartimento di Medicina Sperimentale - Sezione di Fisiopatologia Medica - Sapienza Università di Roma, Rome, Italy
Tadalafil Effects in Left Ventricle Diastolic Dysfunction in Resistant Hypertensive Patients
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- University of Campinas, Brazil
- Target Recruit Count
- 20
- Registration Number
- NCT01743911
- Locations
- 🇧🇷
Laboratory of Cardiovascular Pharmacology - FCM - Unicamp, Campinas, São Paulo, Brazil
A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
- Conditions
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2020-02-28
- Target Recruit Count
- 40
- Registration Number
- NCT01697800
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2018-07-17
- Target Recruit Count
- 30
- Registration Number
- NCT01661595
- Locations
- 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2015-04-21
- Target Recruit Count
- 40
- Registration Number
- NCT01553981
- Locations
- 🇮🇳
SGPGIMS, Lucknow, UP, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.